



Stop TB Partnership

SUMMARY SHEET	
AGENDA NR. 1.12 – 10.0	STOP TB PARTNERSHIP - INITIATIVES PART 1 – RESEARCH MOVEMENT
IS THIS SESSION FOR: INFORMATION <input type="checkbox"/> DISCUSSION <input type="checkbox"/> DECISION <input checked="" type="checkbox"/>	
<p>BACKGROUND (INCLUDING PROBLEM STATEMENT):</p> <p>Following the presentation of the Research Movement (RM) strategic plan at the CB in 2009 in Rio, activities have been carried out in various areas to reach the two objectives of the RM:</p> <ol style="list-style-type: none"> 1. to provide leadership and advocacy to mobilize increased resources in support of a global TB research agenda; 2. to provide a forum for funders and implementers of TB research to coordinate plans and actions, with the result of ensuring that research needs are addressed, opportunities prioritized, and gaps filled. 	
<p>SUMMARY/OUTLINE OF THE SESSION:</p> <ol style="list-style-type: none"> 1. The RM is presently fully launched - a series of documents and papers on TB Research have been published and there is a specially devoted website, that increases its visibility. 2. Global funding of TB research: for 3 consecutive years, we have collaborated with TAG in their annual survey of global TB R&D funding to map out funds that are disbursed in TB research worldwide. This gives a clear description of the landscape of TB R&D funding internationally by categories of research (basic research; diagnostics; drugs; vaccines; operational research and unspecified) and donors (international development agencies, public; private; philanthropy; etc.). Confrontation with the budget estimates indicated in the Global Plan 2011-2015 allows us to estimate the funding gaps and assess the trends since the revision of the Global Plan in 2010. 3. Development of a Global TB Research Agenda: A stepwise process has taken place over the last 2 years, starting with the inventory and mapping of current TB research agendas, followed by a series of thematic workshops assembling research stakeholders in the areas of basic research, R&D for new diagnostics, drugs and vaccines, as well as operational and public health research. As a result, a series of key research questions were identified and prioritized. On this basis, we developed an "<i>International Roadmap for TB research</i>", that is expected to provide a common framework for scientific disciplines to work collaboratively towards better TB control, and to promote the need for more and better coordinated TB research worldwide, including in high-burden countries. The roadmap was presented and discussed at an international strategic meeting in March 2011 in Bellagio, Italy, assembling key scientific thought leaders, representatives from NGOs, the vice-ministers of health of Brazil and South Africa and the top worldwide investors in TB research. Participants agreed that the Research Roadmap was a key vehicle to speed-up and coordinate TB research worldwide, and they proposed that the Roadmap be formally endorsed by the Coordinating Board. It is expected that the roadmap will serve as a reference for activities carried out in support of the research objectives described in the Global Plan 2011-2015 and beyond. 4. On the basis of the activities carried out so far, and the results from a meeting held on 24 January 2012 in Geneva, propositions will be done for the way forward and the role to be played by Secretariat. 	



Stop TB Partnership

MAJOR DISCUSSION POINTS OR DECISION POINTS REQUESTED:

- Endorsement by the Coordinating Board of the International Roadmap for TB Research.
- Endorsement of activities carried out by the RM within the frame of the 2 set objectives, including the production of a guide for TB operational research.
- Discussion and endorsement of the proposed way forward for the RM.

Is this a Special Project? (*i.e. Should be undertaken for strategic reasons and is currently partially or completely unfunded?*)

Yes No

If so, what funding is already available?

What is the funding gap?

Are there HR implications? Yes No . If so, what?

NEXT STEPS

ACTION REQUIRED: N/A

RESPONSIBLE AGENCY/OFFICER: Christian Lienhardt, Senior Research Advisor

TIMEFRAME: N/A